The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2016 | ENDEAVOUR, ASPIRE and TOURMALINE-MM1 trial results for multiple myeloma
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the two trials on second generation proteasome inhibitors. First, Prof Delforge discusses the ENDEAVOUR trial (NCT01568866), which compared carfilzomib plus dexamethasone (Kd) with bortezomib plus dexamethasone (Vd). Progression-free survival doubled in the Kd arm compared to the Vd arm and further, the depth of response was superior in the Kd arm. Prof Delforge also discusses the occurence of side effects such as peripheral neuropathy and cardiovascular toxicity. Prof Delforge further discusses the ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs lenalidomide and dexamethasone (Rd). Finally, he discusses the TOURMALINE-MM1 trial results (NCT01564537) comparing Rd plus placebo and Rd plus ixazumib. Prof Delforge concludes, that proteasome inhibitors have been become indispensible for frontline therapy and in relapse.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
